-
Je něco špatně v tomto záznamu ?
Role of carbonyl reducing enzymes in the phase I biotransformation of the non-steroidal anti-inflammatory drug nabumetone in vitro
L. Skarydova, M. Nobilis, V. Wsól,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- alkoholoxidoreduktasy metabolismus MeSH
- antiflogistika nesteroidní chemie metabolismus MeSH
- biokatalýza účinky léků MeSH
- biotransformace účinky léků MeSH
- butanony chemie metabolismus MeSH
- I. fáze biotransformace * MeSH
- játra účinky léků enzymologie MeSH
- kinetika MeSH
- lidé MeSH
- NADP farmakologie MeSH
- stereoizomerie MeSH
- subcelulární frakce účinky léků metabolismus MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
1. Nabumetone is a clinically used non-steroidal anti-inflammatory drug, its biotransformation includes major active metabolite 6-methoxy-2-naphtylacetic acid and another three phase I as well as corresponding phase II metabolites which are regarded as inactive. One important biotransformation pathway is carbonyl reduction, which leads to the phase I metabolite, reduced nabumetone. 2. The aim of this study is the determination of the role of a particular human liver subcellular fraction in the nabumetone reduction and the identification of participating carbonyl reducing enzymes along with their stereospecificities. 3. Both subcellular fractions take part in the carbonyl reduction of nabumetone and the reduction is at least in vitro the main biotransformation pathway. The activities of eight cytosolic carbonyl reducing enzymes--CBR1, CBR3, AKR1B1, AKR1B10, AKR1C1-4--toward nabumetone were tested. Except for CBR3, all tested reductases transform nabumetone to its reduced metabolite. AKR1C4 and AKR1C3 have the highest intrinsic clearances. 4. The stereospecificity of the majority of the tested enzymes is shifted to the production of an (+)-enantiomer of reduced nabumetone; only AKR1C1 and AKR1C4 produce predominantly an (-)-enantiomer. This project provides for the first time evidence that seven specific carbonyl reducing enzymes participate in nabumetone metabolism.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14064253
- 003
- CZ-PrNML
- 005
- 20140708083812.0
- 007
- ta
- 008
- 140704s2013 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3109/00498254.2012.720048 $2 doi
- 035 __
- $a (PubMed)23020786
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Skarydova, Lucie $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Czech Republic.
- 245 10
- $a Role of carbonyl reducing enzymes in the phase I biotransformation of the non-steroidal anti-inflammatory drug nabumetone in vitro / $c L. Skarydova, M. Nobilis, V. Wsól,
- 520 9_
- $a 1. Nabumetone is a clinically used non-steroidal anti-inflammatory drug, its biotransformation includes major active metabolite 6-methoxy-2-naphtylacetic acid and another three phase I as well as corresponding phase II metabolites which are regarded as inactive. One important biotransformation pathway is carbonyl reduction, which leads to the phase I metabolite, reduced nabumetone. 2. The aim of this study is the determination of the role of a particular human liver subcellular fraction in the nabumetone reduction and the identification of participating carbonyl reducing enzymes along with their stereospecificities. 3. Both subcellular fractions take part in the carbonyl reduction of nabumetone and the reduction is at least in vitro the main biotransformation pathway. The activities of eight cytosolic carbonyl reducing enzymes--CBR1, CBR3, AKR1B1, AKR1B10, AKR1C1-4--toward nabumetone were tested. Except for CBR3, all tested reductases transform nabumetone to its reduced metabolite. AKR1C4 and AKR1C3 have the highest intrinsic clearances. 4. The stereospecificity of the majority of the tested enzymes is shifted to the production of an (+)-enantiomer of reduced nabumetone; only AKR1C1 and AKR1C4 produce predominantly an (-)-enantiomer. This project provides for the first time evidence that seven specific carbonyl reducing enzymes participate in nabumetone metabolism.
- 650 _2
- $a alkoholoxidoreduktasy $x metabolismus $7 D000429
- 650 _2
- $a antiflogistika nesteroidní $x chemie $x metabolismus $7 D000894
- 650 _2
- $a biokatalýza $x účinky léků $7 D055162
- 650 _2
- $a biotransformace $x účinky léků $7 D001711
- 650 _2
- $a butanony $x chemie $x metabolismus $7 D002074
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kinetika $7 D007700
- 650 _2
- $a játra $x účinky léků $x enzymologie $7 D008099
- 650 12
- $a I. fáze biotransformace $7 D050216
- 650 _2
- $a NADP $x farmakologie $7 D009249
- 650 _2
- $a stereoizomerie $7 D013237
- 650 _2
- $a subcelulární frakce $x účinky léků $x metabolismus $7 D013347
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Nobilis, Milan
- 700 1_
- $a Wsól, Vladimir
- 773 0_
- $w MED00004746 $t Xenobiotica; the fate of foreign compounds in biological systems $x 1366-5928 $g Roč. 43, č. 4 (2013), s. 346-54
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23020786 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20140704 $b ABA008
- 991 __
- $a 20140708084102 $b ABA008
- 999 __
- $a ok $b bmc $g 1031737 $s 862985
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 43 $c 4 $d 346-54 $i 1366-5928 $m Xenobiotica $n Xenobiotica $x MED00004746
- LZP __
- $a Pubmed-20140704